Lonza Pharma & Biotech and Innosieve Diagnostics announced today an exclusive distribution agreement for rapid bioburden testing technology. This agreement expands Lonza’s extensive offering of ...
The bioburden testing market is projected to experience significant growth due to the increasing demand for quality assurance and safety measures in various industries. The rising awareness about the ...
As biopharma companies fine-tune their strategies for continuous bioprocessing, bioburden control has become a top priority. The approaches that worked for batch processing are inadequate for ...
WILMINGTON, Mass.—October 20, 2014 – Charles River Laboratories International, Inc. (NYSE: CRL) today introduced the PTS-Micro™ system, a new technology platform designed for rapid microbial burden ...
(MENAFN- GlobeNewsWire - Nasdaq) The bioburden testing market is set to grow significantly due to increased demand in pharmaceuticals and medical devices and strict regulatory standards. Key ...
Another driver contributing to the market growth is the growing emphasis on regulatory compliance. Regulatory authorities across the globe are imposing strict guidelines and regulations regarding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results